111, Inc. [YI] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

YI Stock Summary

Earnings have grown 8.78% per last year.

Earnings are expected to fall -100% next year

EPS has been decreasing for the past 3 quarters (Quarter statements)

YI has less than 1 year of cash runway

Top 10 Correlated ETFs

YI

Top 10 Correlated Stocks

YI

In the News

YI Financial details

Company Rating

Neutral

Market Cap

97.02M

Income

-282.98M

Revenue

14.99B

Book val./share

-6.07

Cash/share

9.95

Dividend

Dividend %

Employees

1.66K

Optionable

Shortable

Yes

Earnings

13 Jun 2024

P/E

-3.23

Forward P/E

PEG

0.56

P/S

0.06

P/B

-1.78

P/C

0.1

P/FCF

-11.79

Quick Ratio

0.5

Current Ratio

1.07

Debt / Equity

-0.81

LT Debt / Equity

0.21

EPS (TTM)

-3.37

EPS next Y

EPS next Q

EPS this Y

-38.67%

EPS next Y

EPS next 5Y

EPS last 5Y

-8.5%

Revenue last 5Y

49.9%

Revenue Q/Q

5.4%

EPS Q/Q

61.76%

SMA20

SMA50

SMA100

-50%

Inst Own

1.02%

Inst Trans

0.47%

ROA

-8%

ROE

63%

ROC

-0.66%

Gross Margin

Oper. Margin

-2%

Profit Margin

-2%

Payout

Shs Outstand

Shs Float

Target Price

52W Range

0.98-3.36

52W High

52W Low

RSI

Rel Volume

0.38

Avg Volume

70.49K

Volume

27.12K

Perf Week

-14.77%

Perf Month

-29.49%

Perf Quarter

-54.83%

Perf Half Y

-61.86%

Beta

0.338

Volatility

0.05%, 0.18%

Prev Close

-1.99%

Price

0.9801

Change

-3.91%

YI Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	35.92	48.29	99.56	149.83	162.23
Net income per share	-7.64	-6.02	-5.57	-7.99	-4.9
Operating cash flow per share	-6.9	-6.23	-1.42	-7.74	-0.28
Free cash flow per share	-7.2	-6.54	-1.73	-8.5	-0.66
Cash per share	22.25	7.5	18.08	10.18	10.56
Book value per share	24.62	9.49	4.34	-2.09	-4.98
Tangible book value per share	24.52	9.36	16.07	10.17	7.74
Share holders equity per share	24.62	9.49	4.34	-2.09	-4.98
Interest debt per share	0.05	1.9	3.65	5.19	3.52
Market cap	2.1B	3.83B	3.74B	1.85B	1.74B
Enterprise value	1.25B	3.37B	2.84B	1.61B	1.34B
P/E ratio	-5.52	-7.78	-8.14	-2.79	-4.25
Price to sales ratio	1.18	0.97	0.46	0.15	0.13
POCF ratio	-6.12	-7.51	-32	-2.88	-74.95
PFCF ratio	-5.87	-7.17	-26.26	-2.62	-31.71
P/B Ratio	1.71	4.93	10.46	-10.67	-4.19
PTB ratio	1.71	4.93	10.46	-10.67	-4.19
EV to sales	0.7	0.85	0.35	0.13	0.1
Enterprise value over EBITDA	-3.24	-6.91	-6.12	-2.61	-3.78
EV to operating cash flow	-3.63	-6.61	-24.31	-2.51	-57.93
EV to free cash flow	-3.48	-6.3	-19.95	-2.29	-24.51
Earnings yield	-0.18	-0.13	-0.12	-0.36	-0.24
Free cash flow yield	-0.17	-0.14	-0.04	-0.38	-0.03
Debt to equity	0	0.2	0.82	-2.45	-0.67
Debt to assets	0	0.09	0.1	0.14	0.08
Net debt to EBITDA	2.22	0.95	1.94	0.38	1.11
Current ratio	4.79	1.99	1.76	1.32	1.19
Interest coverage	0	-136.25	-53.68	-117.01	-27.6
Income quality	0.9	1.02	0.26	1.03	0.06
Dividend Yield	0	0.04	0.07	0.19	0
Payout ratio	0	-0.3	-0.58	-0.54	0
Sales general and administrative to revenue	0.14	0.08	0.05	0.06	0.06
Research and developement to revenue	0	0.02	0.01	0.02	0.01
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0.04	0.05	0.22	0.1	1.36
Capex to revenue	-0.01	-0.01	0	-0.01	0
Capex to depreciation	-1.32	-2.11	-1.82	-2.3	-0.77
Stock based compensation to revenue	0.03	0.01	0.01	0.01	0.01
Graham number	65.07	35.84	23.32	19.39	23.43
ROIC	-0.33	-0.49	-0.65	-1.64	11.62
Return on tangible assets	-0.25	-0.31	-0.15	-0.21	-0.12
Graham Net	18.32	1.06	3.75	-6.28	-9.57
Working capital	1.19B	735.8M	1.24B	671.76M	510.72M
Tangible asset value	1.22B	765.9M	1.32B	843.8M	644.97M
Net current asset value	1.18B	645.06M	1.18B	504.61M	410.25M
Invested capital	0	0.2	0.82	-2.45	-0.67
Average receivables	62.02M	58.7M	132.26M	335.44M	513.71M
Average payables	170.2M	314.4M	744.95M	1.23B	1.58B
Average inventory	177.45M	348.55M	626.4M	943.82M	1.31B
Days sales outstanding	5.84	8.2	7.82	14.55	14.37
Days payables outstanding	46.07	40.15	49.99	43.11	50.82
Days of inventory on hand	45.76	46.87	35.7	34.66	43.16
Receivables turnover	62.51	44.49	46.69	25.09	25.4
Payables turnover	7.92	9.09	7.3	8.47	7.18
Inventory turnover	7.98	7.79	10.22	10.53	8.46
ROE	-0.31	-0.63	-1.28	3.83	0.99
Capex per share	-0.3	-0.3	-0.31	-0.76	-0.38

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric	2022-09-30	2022-12-31	2023-03-31	2023-06-30	2023-09-30
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	40.17	49.71	44.19	41.37	43.35
Net income per share	-1.18	-1.29	-0.3	-0.68	-1.1
Operating cash flow per share	0.14	0.76	-1.45	-0.27	0.42
Free cash flow per share	0.14	0.38	-1.45	-0.27	0.42
Cash per share	9.93	10.54	10.09	8.32	9.95
Book value per share	-4.45	-4.97	-5.06	-5.31	-6.07
Tangible book value per share	8.14	7.73	7.75	7.59	3.7
Share holders equity per share	-4.45	-4.97	-5.06	-5.31	-6.07
Interest debt per share	4.19	3.38	4.3	4.8	4.96
Market cap	1.59B	1.74B	1.52B	1.5B	1.6B
Enterprise value	1.22B	1.34B	1.29B	1.32B	1.29B
P/E ratio	-4.05	-4.05	-15.15	-6.55	-4.3
Price to sales ratio	0.48	0.42	0.41	0.43	0.44
POCF ratio	134.7	27.5	-12.55	-66.24	45.58
PFCF ratio	134.7	54.94	-12.55	-66.24	45.58
P/B Ratio	-4.29	-4.19	-3.6	-3.36	-3.13
PTB ratio	-4.29	-4.19	-3.6	-3.36	-3.13
EV to sales	0.36	0.32	0.35	0.38	0.35
Enterprise value over EBITDA	-15.82	-13.04	-77.43	-35	-16.51
EV to operating cash flow	102.87	21.26	-10.67	-58.37	36.59
EV to free cash flow	102.87	42.48	-10.67	-58.37	36.59
Earnings yield	-0.06	-0.06	-0.02	-0.04	-0.06
Free cash flow yield	0.01	0.02	-0.08	-0.02	0.02
Debt to equity	-0.93	-0.67	-0.84	-0.89	-0.81
Debt to assets	0.11	0.08	0.11	0.13	0.12
Net debt to EBITDA	4.89	3.82	13.68	4.72	4.06
Current ratio	1.24	1.19	1.21	1.22	1.07
Interest coverage	-18.77	-39.04	-5.09	-8.59	-14.8
Income quality	-0.12	-0.24	3.82	0.4	-0.38
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0.05	0.06	0.05	0.01	0.01
Research and developement to revenue	0.01	0.01	0.01	0.01	0.01
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0	-0.5	0	0	0
Capex to revenue	0	-0.01	0	0	0
Capex to depreciation	0	-0.77	0	0	0
Stock based compensation to revenue	0.01	0.04	0.01	0.01	0.01
Graham number	10.85	11.99	5.85	9.02	12.28
ROIC	-1.03	3.22	-1.54	-1.34	2.35
Return on tangible assets	-0.03	-0.03	-0.01	-0.02	-0.03
Graham Net	-6.63	-9.56	-7.75	-7.49	-11.49
Working capital	533.83M	510.72M	518.29M	511.29M	213.68M
Tangible asset value	678.16M	644.97M	648.65M	638.04M	312.78M
Net current asset value	418.9M	410.25M	432.37M	422.65M	148.86M
Invested capital	-0.93	-0.67	-0.84	-0.89	-0.81
Average receivables	509.67M	514.15M	506.6M	498.46M	586.21M
Average payables	1.53B	1.66B	1.72B	1.6B	1.66B
Average inventory	1.23B	1.37B	1.48B	1.43B	1.43B
Days sales outstanding	13.33	11.55	11.71	13.35	16.12
Days payables outstanding	44.27	40.78	43.73	41.64	47.01
Days of inventory on hand	35.51	34.64	38.18	38.2	38.37
Receivables turnover	6.75	7.79	7.69	6.74	5.58
Payables turnover	2.03	2.21	2.06	2.16	1.91
Inventory turnover	2.53	2.6	2.36	2.36	2.35
ROE	0.26	0.26	0.06	0.13	0.18
Capex per share	0	-0.38	0	0	0

YI Frequently Asked Questions

What is 111, Inc. stock symbol ?

111, Inc. is a CN stock and trading under the symbol YI

What is 111, Inc. stock quote today ?

111, Inc. stock price is $0.9801 today.

Is 111, Inc. stock public?

Yes, 111, Inc. is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 70.49K
Market Capitalization 97.02M
Employee 1.66K
CEO Mr. Junling Liu
Headquarters Shanghai,CN
IPO Date 2018-09-12
Website https://www.111.com.cn

111, Inc. operates an integrated online and offline platform in the healthcare market in the People's Republic of China. It operates through two segments, B2B and B2C. The company sells medical and wellness products through online retail, and wholesale and retail pharmacies, as well as provides value-added services that include online consultation services and electronic prescription services to consumers. It offers prescription and over-the counter drugs, including western and traditional Chinese medicines; nutritional supplements, such as vitamins and dietary products; contact lenses; medical supplies and devices comprising bandages and thermometers; and personal care products consisting of skin care, birth control, and sexual wellness products; and baby products. The company also operates an online marketplace where third-party sellers can directly sell to pharmacies; provides online loan application services to the clients of 1 Pharmacy, which include pharmacies and wholesalers; and data and supply chain integration services. As of December 31, 2021, it operated 14 offline retail pharmacies under the Yi Hao Pharmacy brand name in Guangzhou, Tianjin, Kunshan, Chongqing, and Wuhan provinces. In addition, the company offers warehousing, logistics, procurement, research and development, and consulting services; and software development and information technology support services. It serves pharmacies, pharmaceutical companies and distributors, medical professionals, and insurance companies. The company was formerly known as New Peak Group and changed its name to 111, Inc. in April 2018. 111, Inc. was founded in 2010 and is headquartered in Shanghai, the People's Republic of China.